A Single Centre, Open Label Trial Investigating the Absorption, Metabolism and Excretion of Somapacitan After Single Subcutaneous Dosing in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 20 Mar 2018
At a glance
- Drugs Somapacitan (Primary)
- Indications Somatotropin deficiency
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 20 Mar 2018 Results assessing the absorption, metabolism and excretion in healthy male subjects after a single s.c. administration of tritium [3H]-somapacitan, presented at The 100th Annual Meeting of the Endocrine Society.
- 03 Feb 2017 Status changed from recruiting to completed.
- 28 Nov 2016 Status changed from not yet recruiting to recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History